Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study

MLA

Joseph Kerger, et al. “Docetaxel Combined with Irinotecan or 5-Fluorouracil in Patients with Advanced Oesophago-Gastric Cancer: A Randomised Phase II Study.” British Journal of Cancer, vol. 107, July 2012, pp. 435–41. EBSCOhost, https://doi.org/10.1038/bjc.2012.286.

APA

Joseph Kerger, F. Lofts, Halfdan Sorbye, Patrick Schöffski, O. Rixe, D K Hossfeld, J Aparicio, Robert E. Hawkins, A Schalhorn, J.-L. Misset, David Cunningham, J Cassinello, Lionel D’Hondt, M Mousseau, Marianne Nicolson, J-L Canon, C Garcia Giron, E Fonseca, Amitesh Roy, … Guillermo Lopez-Vivanco. (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer, 107, 435–441. https://doi.org/10.1038/bjc.2012.286

Chicago

Joseph Kerger, F. Lofts, Halfdan Sorbye, Patrick Schöffski, O. Rixe, D K Hossfeld, J Aparicio, et al. 2012. “Docetaxel Combined with Irinotecan or 5-Fluorouracil in Patients with Advanced Oesophago-Gastric Cancer: A Randomised Phase II Study.” British Journal of Cancer 107 (July): 435–41. doi:10.1038/bjc.2012.286.